aflibercept   Click here for help

GtoPdb Ligand ID: 6786

Synonyms: AVE0005 | Eylea® | VEGF Trap | Zaltrap® | ziv-aflibercept
Approved drug
aflibercept is an approved drug (FDA (2011), EMA (2012))
Compound class: Antibody
Comment: Alfibercept is a fusion protein combining the Fc portion of human IgG with the ligand binding domains of the VEGRF1 and VEGRF2 receptors.

Biosimilars:
Patent protection for originator alfibercept is expected to expire earliest in Japan and China (2022), then in US (2023, if Regeneron's extended patent claims are accepted) and the EU (2025), and biosimilar development is underway [3]. Examples include Momenta Pharmaceuticals/Mylan's M710, Alteogen's ALT-L9 (a heat stabilised formulation with a predicted longer shelf-life than Eylea; NCT04058535), and Formycon/Santo Holdings' FYB203.
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2011), EMA (2012))
International Nonproprietary Names Click here for help
INN number INN
8739 aflibercept
Synonyms Click here for help
AVE0005 | Eylea® | VEGF Trap | Zaltrap® | ziv-aflibercept
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 214
Reactome Drug Reactome logo R-ALL-9679475
Reactome Reaction Reactome logo R-HSA-9679477
Other databases
CAS Registry No. 862111-32-8
ChEMBL Ligand CHEMBL1742982
DrugBank Ligand DB08885
GtoPdb PubChem SID 178103392
PubChem SID 135347926
Search PubMed clinical trials aflibercept
Search PubMed titles aflibercept
Search PubMed titles/abstracts aflibercept
Wikipedia Aflibercept